Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Vitiligo
Interventions: Afamelanotide; Drug
Lead sponsor: Clinuvel, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer
Interventions: Lapatinib, Paclitaxel, 5-Fluorouracil (5-FU), Epirubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Stereotactic Ablative Radiation Therapy (SABR); Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
Interventions: MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]; Drug
Lead sponsor: 4D pharma plc; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Patients Undergoing Repeat Peripheral Artery Revascularization
Interventions: CV-18C3, Standard of Care; Drug · Procedure
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Sacramento, California • Atlantis, Florida • Jacksonville, Florida + 4 more

Conditions: Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Gainesville, Florida • Oklahoma City, Oklahoma

Conditions: Anemia
Interventions: Methoxy Polyethylene Glycol-Epoetin Beta, Epoetin alfa, Epoetin beta, Darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 69 more

Conditions: Urothelial Carcinoma
Interventions: AEZS-108, AEZS-108 at MTD; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Philadelphia, Pennsylvania

Conditions: Opioid Overdose
Interventions: Observation only; Other
Lead sponsor: Member Companies of the Opioid PMR Consortium; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 808,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Wilmington, Delaware • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Multiple Myeloma
Interventions: bortezomib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: Myasthenia Gravis
Interventions: ARGX-113, Placebo; Biological · Drug
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Tampa, Florida + 3 more

Conditions: Endometrial Cancer
Interventions: Carboplatin/Paclitaxel, Trastuzumab; Drug
Lead sponsor: Yale University; Other
Eligibility: Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more

Conditions: Short Stature Children Born Small for Gestational Age (SGA)
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more

Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PS-341, Doxil, Velcade; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Prevention
Interventions: HIV Risk Reduction (HIVRR), PrEP Peer Supporters (PS), Matched Savings Accounts + Financial Literacy (FL); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 15 Years to 24 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Neoplasms
Interventions: Mammosite brachytherapy radiation; Radiation
Lead sponsor: Yale University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Macular Edema
Interventions: 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Portland, Maine • Worcester, Massachusetts • Lebanon, New Hampshire + 1 more

Conditions: Irritable Bowel Syndrome
Interventions: Blautix, Placebo; Biological · Other
Lead sponsor: 4D pharma plc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more

Conditions: Colorectal Cancer
Interventions: Capecitabine (Xeloda), Bevacizumab; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 9 more

Conditions: Depression, Hemodialysis-Induced Symptom
Interventions: Fluoxetine; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Rexin-G; Genetic
Lead sponsor: Epeius Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Marino, California • Santa Monica, California • New York, New York

Search by objective public record fields.

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Phase II Neoadjuvant in Inflammatory Breast Cancer

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

SABR for T1-2a N1 NSCLC

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda

Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

HOBSCOTCH Phase II

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

Identifying and Treating Depression in Hemodialysis Patients

Safety and Efficacy Study Using Rexin-G for Breast Cancer